NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCATS E-120-2010-0-US-07 Activators Of Human Pyruvate Kinase US National Stage 13/643,594 Abandoned
NCI E-224-2011-0-CN-03 METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR CN National Stage 2012800648297 Abandoned
NCI E-224-2011-0-EP-04 METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR EP National Stage 12783789.6 Abandoned
NCATS E-091-2013-1-US-01 Method For Identifying And Identification Of Small Molecule Inhibitors Of SIX/EYA Interaction For The Treatment Of Cancers US 61/718,682 Abandoned
NCATS E-091-2013-0-US-01 Method For Identifying And Identification Of Small Molecule Inhibitors Of SIX/EYA Interaction For The Treatment Of Cancers US 61/718,659 Abandoned
NCI E-074-2007-0-HK-11 BRACHYURY POLYPEPTIDES AND METHODS FOR USE HK EP 12110614.1 Pending
NCI E-291-2012-0-US-01 M971 Chimeric Antigen Receptors US 61/717,960 Abandoned
NCI E-054-2013-0-US-01 THERAPEUTIC USES OF IL-15 AND IL-15RALPHA HETERODIMER COMPLEXES US 61/718,169 Abandoned
NCI E-272-2012-0-US-01 Compositions And Methods For Enhancing Cancer Immunotherapy US 61/716,653 Abandoned
NCI E-265-2011-0-IN-08 Anti-CD22 Chimeric Antigen Receptors IN National Stage 2906/CHENP/2014 Abandoned
NCI E-265-2011-0-CA-05 Anti-CD22 Chimeric Antigen Receptors CA National Stage 2851795 Abandoned
NCI E-265-2011-0-EP-07 Anti-CD22 Chimeric Antigen Receptors EP National Stage 12781544.7 Abandoned
NCI E-265-2011-0-PCT-02 Anti-CD22 Chimeric Antigen Receptors PCT PCT PCT/US2012/061025 Expired
NIEHS E-180-2011-5-US-01 METHOD OF IDENTIFYING AND TREATING A PATIENT HAVING A GENETIC PREDISPOSITION TO PARKINSON DISEASE US CIP 13/574,000 Abandoned
NCI E-265-2011-0-AU-03 Anti-CD22 Chimeric Antigen Receptors AU National Stage 2012325915 Abandoned
NCI E-220-2011-0-AU-03 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER AU National Stage 2012326105 Issued
NCI E-220-2011-0-EP-05 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER EP National Stage 12841601.3 Issued
NCI E-220-2011-0-PCT-02 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER PCT PCT PCT/US2012/060785 Expired
NCATS E-010-2013-0-US-01 Point of Care Detection of Hyperammonemia and Aminoacidopathies US 61/714,870 Expired
NCI E-212-2011-0-PCT-02 Monospecific And Bispecific Human Monoclonal Antibodies Targeting Insulin-Like Growth Factor II (IGF-II) PCT PCT PCT/US2012/060443 Expired
NIA E-092-2011-0-CN-11 The Use Of (2r, 6r)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (R,S)- Ketamine In The Treatment Of Depression And Neuropathic Pain CN DIV 201910105053.2 Issued
NIA E-092-2011-0-IT-18 The Use Of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain IT EP 12783752.4 Issued
NIA E-092-2011-0-ES-17 The Use Of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain ES EP 12783752.4 Issued
NIA E-092-2011-0-DE-14 The Use Of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain DE EP 12783752.4 Issued
NIA E-092-2011-0-FR-15 The Use Of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain FR EP 12783752.4 Issued
NIA E-092-2011-0-GB-16 The Use Of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain GB EP 12783752.4 Issued
NIA E-092-2011-0-EP-06 The Use Of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain EP National Stage 12783752.4 Issued
NIA E-092-2011-0-AU-03 The Use Of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain AU National Stage 2012323845 Issued
NIA E-092-2011-0-PCT-02 The Use Of (2S,6S)-hydroxynorketamine And Other Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression PCT PCT PCT/US12/60256 Expired
NCATS E-109-2010-0-US-06 Arylthiazolyl Piperidines And Related Compounds As Modulators Of Survival Motor Neuron (SMN) Protein Production US National Stage 13/641,383 Abandoned
NIAAA E-211-2006-0-US-07 Therapeutic Applications Of Fatty Acid Amide Hydrolase Inhibitors US CON 13/652,324 Abandoned
NIA E-092-2011-0-CN-05 The Use Of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain CN National Stage 201280062294X Abandoned
NIDCR E-114-2003-0-US-05 Methods and Compositions for the Inhibition of HIV-1 Replication US DIV 13/650,526 Abandoned
NCI E-239-2009-0-US-03 DNA-Protein Vaccination Protocols US National Stage 13/580,892 Abandoned
NCI E-161-2010-0-US-06 PROGNOSTIC MARKERS AND METHODS FOR PROSTATE CANCER US National Stage 13/641,066 Abandoned
CC E-013-2013-0-US-01 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND US 61/713,132 Abandoned
NCI E-181-2006-0-AU-14 Micro-RNA Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer AU DIV 2012238336 Abandoned
NIA E-189-2003-0-US-16 Thiothalidomides: Novel Isoteric Analogues Of Thalidomide With Enhanced TNF-a Inhibitory Activity US CON 13/648,625 8853253 Abandoned PDF
NCI E-239-2011-0-PCT-02 THIOXOTHIAZOLIDINONE DERIVATIVES USEFUL AS INHIBITORS OF TDP1 PCT PCT PCT/US2012/059515 Expired
NHLBI E-261-2012-0-US-01 Imaging Methods and Computer-Readable Media US 61/711,702 Abandoned
NCI E-268-2012-0-US-03 Discovery Of Niclosamide As A Lead For Inlnbition Of S100A4 Transcription And Metastasis US National Stage 14/112,521 Abandoned
NIDCR E-282-2009-0-US-05 SUSTAINED RELEASE DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF HEAD AND NECK CANCERS US National Stage 13/391,756 10485792 Abandoned PDF
NCI E-217-2011-0-PCT-02 GENETIC MARKER FOR PREDICTING PROGNOSIS IN PATIENTS INFECTED WITH HEPATITIS C VIRUS PCT PCT PCT/US2012/59048 Expired
NCATS E-217-2013-0-US-01 A new chemical entity useful for treating various diseases US 61/710,505 Abandoned
NCI E-227-2006-5-CA-03 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS CA National Stage 2665287 Issued
NCI E-269-2009-0-RU-09 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity RU National Stage 2012114005 Abandoned
NIAID E-089-2012-0-US-01 A Formulation Of Mycobacterial Components As An Adjuvant For Inducing Th17 Response US 61/709,713 Abandoned
NCI E-197-2011-0-PCT-02 Use Of MIRNA126 To Produce Hematopoietic Stem Cells PCT PCT PCT/US2012/000472 Expired
NIAID E-158-2007-3-US-03 LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE US DIV 13/633,633 9255252 Abandoned PDF
NCI E-034-2010-0-US-03 B- Mannosylceramide And Stimulation Of NKT Cell Anti-Tumor Immunity US National Stage 13/582,612 8835613 Issued PDF